Legacy Wealth Asset Management LLC Purchases New Shares in BioNTech SE (NASDAQ:BNTX)

Legacy Wealth Asset Management LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 6,525 shares of the company’s stock, valued at approximately $602,000.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares in the last quarter. CWM LLC increased its position in BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after buying an additional 217 shares during the period. Frazier Financial Advisors LLC acquired a new stake in shares of BioNTech during the fourth quarter worth $30,000. First Horizon Advisors Inc. acquired a new stake in BioNTech in the 4th quarter worth about $38,000. Finally, UMB Bank n.a. bought a new stake in shares of BioNTech in the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. UBS Group decreased their price objective on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research note on Thursday, March 21st. HC Wainwright reiterated a “buy” rating and set a $113.00 price target on shares of BioNTech in a report on Wednesday, June 26th. JPMorgan Chase & Co. cut their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. Finally, BMO Capital Markets reduced their target price on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research note on Tuesday, May 7th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, BioNTech presently has an average rating of “Hold” and an average target price of $111.70.

BioNTech Trading Up 1.4 %

NASDAQ:BNTX opened at $79.86 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. The firm has a market cap of $18.99 billion, a price-to-earnings ratio of 159.72 and a beta of 0.23. The firm has a 50-day moving average price of $91.54 and a two-hundred day moving average price of $94.11. BioNTech SE has a 52 week low of $78.02 and a 52 week high of $125.83.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, May 6th. The company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.60). BioNTech had a return on equity of 0.55% and a net margin of 4.01%. The company had revenue of $203.69 million during the quarter, compared to the consensus estimate of $589.96 million. On average, equities analysts expect that BioNTech SE will post -2 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.